Free Trial
NASDAQ:SBTX

Silverback Therapeutics (SBTX) Stock Price, News & Analysis

Silverback Therapeutics logo
$13.82 -0.71 (-4.89%)
As of 06/4/2025

About Silverback Therapeutics Stock (NASDAQ:SBTX)

Key Stats

Today's Range
$13.79
$14.70
50-Day Range
$12.10
$15.49
52-Week Range
$2.80
$8.97
Volume
847,918 shs
Average Volume
337,931 shs
Market Capitalization
$498.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Stock News Headlines

ARS Pharmaceuticals Inc (SPRY)
SPRY ARS Pharmaceuticals, Inc.
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

SBTX Stock Analysis - Frequently Asked Questions

Silverback Therapeutics' stock was trading at $10.55 at the beginning of 2025. Since then, SBTX shares have increased by 37.7% and is now trading at $14.53.
View the best growth stocks for 2025 here
.

Silverback Therapeutics, Inc. (NASDAQ:SBTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65).

Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silverback Therapeutics investors own include Athenex (ATNX), AbbVie (ABBV), Applied Materials (AMAT), JPMorgan Chase & Co. (JPM), Luminar Technologies (LAZR), Lineage Cell Therapeutics (LCTX) and Aviat Networks (AVNW).

Company Calendar

Last Earnings
11/10/2021
Today
6/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBTX
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$89.48 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$7.41 per share
Price / Book
1.96

Miscellaneous

Free Float
23,654,000
Market Cap
$523.92 million
Optionable
Not Optionable
Beta
0.60
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:SBTX) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners